Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Umbrella Brand Debate Lives On At FDA Naming Workshop

This article was originally published in The Tan Sheet

Executive Summary

Critics of drug labels' effectiveness say reducing errors in the use of OTC drugs depends largely on a change manufacturers oppose - reining in umbrella branding
Advertisement

Related Content

OTC Umbrella Branding Soaked By Regulatory Storm In Draft Guidance – CHPA
OTC Umbrella Branding Soaked By Regulatory Storm In Draft Guidance – CHPA
OTC Umbrella Branding Soaked By Regulatory Storm In Draft Guidance – CHPA
OTC Umbrella Branding Soaked By Regulatory Storm In Draft Guidance – CHPA
OTC Firms Should Improve Monograph Compliance, Registration – CDER
OTC Firms Should Improve Monograph Compliance, Registration – CDER
RAPS Annual Conference In Brief
McNeil Exec Calls For Uniform Use Of "Acetaminophen" Name
J&J revises Benadryl topical labels to reduce confusion
Novartis' Maalox Total Relief Rebranding Reflects FDA AER Evolution

Topics

Advertisement
UsernamePublicRestriction

Register

PS104279

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel